Hull, Mark A, Ow, Pei Loo, Ruddock, Sharon, Brend, Tim, Smith, Alexandra F, Marshall, Helen, Song, Mingyang, Chan, Andrew T, Garrett, Wendy S, Yilmaz, Omer et al (show 9 more authors)
(2023)
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.
BMJ open, 13 (11).
e077427-e077427.
Abstract
<h4>Introduction</h4>There remains an unmet need for safe and cost-effective adjunctive treatment of advanced colorectal cancer (CRC). The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) is safe, well-tolerated and has anti-inflammatory as well as antineoplastic properties. A phase 2 randomised trial of preoperative EPA free fatty acid 2 g daily in patients undergoing surgery for CRC liver metastasis showed no difference in the primary endpoint (histological tumour proliferation index) compared with placebo. However, the trial demonstrated possible benefit for the prespecified exploratory endpoint of postoperative disease-free survival. Therefore, we tested the hypothesis that EPA treatment, started before liver resection surgery (and continued postoperatively), improves CRC outcomes in patients with CRC liver metastasis.<h4>Methods and analysis</h4>The EPA for Metastasis Trial 2 trial is a randomised, double-blind, placebo-controlled, phase 3 trial of 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily in patients undergoing liver resection surgery for CRC liver metastasis with curative intent. Trial treatment continues for a minimum of 2 years and maximum of 4 years, with 6 monthly assessments, including quality of life outcomes, as well as annual clinical record review after the trial intervention. The primary endpoint is CRC progression-free survival. Key secondary endpoints are overall survival, as well as the safety and tolerability of IPE. A minimum 388 participants are estimated to provide 247 CRC progression events during minimum 2-year follow-up, allowing detection of an HR of 0.7 in favour of IPE, with a power of 80% at the 5% (two sided) level of significance, assuming drop-out of 15%.<h4>Ethics and dissemination</h4>Ethical and health research authority approval was obtained in January 2018. All data will be collected by 2025. Full trial results will be published in 2026. Secondary analyses of health economic data, biomarker studies and other translational work will be published subsequently.<h4>Trial registration number</h4>NCT03428477.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Recurrence, Local, Eicosapentaenoic Acid, Treatment Outcome, Double-Blind Method, Quality of Life, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 02 Feb 2024 10:25 |
| Last Modified: | 02 Feb 2024 10:25 |
| DOI: | 10.1136/bmjopen-2023-077427 |
| Open Access URL: | https://bmjopen.bmj.com/content/13/11/e077427 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178321 |
Dimensions
Dimensions
